Jane Wan

 jayk7/Getty Images

Chinese healthcare reforms may be a double-edged sword for foreign companies.

Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.

Industry players brace themselves to face challenges as India's new drug-pricing policy kicks in full gear.

The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.

The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.

India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.

The South Korean market is characterized by its aging population and an affluent population. Growth potential is limited as it has evolved to a developed market and industry players expect it to have established regulations.

India has enforced stricter patent laws compared to other countries. For a drug to be patentable in India, the invention has to be novel, inventive, and industrially applicable.

After a series of government reforms, the Japanese pharma market is making a comeback.